Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14944MR)

This product GTTS-WQ14944MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14944MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12320MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ1132MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ3910MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ7282MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ9325MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ2688MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ5463MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ1767MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW